Advancing American Kidney Health and the Role of Sodium-Glucose Cotransporter-2 Inhibitors: A Missed Opportunity

Clin J Am Soc Nephrol. 2021 Oct;16(10):1584-1586. doi: 10.2215/CJN.05450421. Epub 2021 Jun 16.
No abstract available

Keywords: SGLT2i; United States; chronic kidney disease; diabetes mellitus; proteinuria; sodium-glucose transporter 2; sodium-glucose transporter 2 inhibitors; type 2.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Clinical Trials as Topic
  • Delivery of Health Care, Integrated / legislation & jurisprudence
  • Delivery of Health Care, Integrated / organization & administration*
  • Evidence-Based Medicine
  • Glomerular Filtration Rate / drug effects*
  • Government Regulation
  • Health Policy
  • Humans
  • Kidney / drug effects*
  • Kidney / physiopathology
  • Renal Insufficiency, Chronic / diagnosis
  • Renal Insufficiency, Chronic / drug therapy*
  • Renal Insufficiency, Chronic / epidemiology
  • Renal Insufficiency, Chronic / physiopathology
  • Sodium-Glucose Transporter 2 Inhibitors / adverse effects
  • Sodium-Glucose Transporter 2 Inhibitors / therapeutic use*
  • Treatment Outcome
  • United States / epidemiology

Substances

  • Sodium-Glucose Transporter 2 Inhibitors